BETA
Your AI-Trained Oncology Knowledge Connection!
Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Large B-Cell Lymphoma
In a multicenter retrospective study authors examined the impact of prior inotuzumab ozogamicin exposure on the outcomes of brexu-cel therapy in adults with R/R B-cell ALL.
Lung Cancer Screening Adherence Decreases Across Subsequent Testing
Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Researchers conducted a comprehensive review on how intrinsic T cell characteristics influence CAR-T cell therapy outcomes in hematological malignancies.
FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors
The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.
FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma
Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.
Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care
Polypharmacy, medication list errors, and drug-drug interactions were all observed in patients with cancer receiving oral anticancer drugs.
CAR T, Targeted Therapies, Others as Treatment Options on the Horizon in NETs
The NETRF lends funding to help discover new and emerging treatment options in neuroendocrine tumors, according to Anna Greene, PhD.
Tislelizumab Significantly Boosts Survival in Lung Cancer Trials
A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study
TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer
Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.
New Legislation May Help Reduce Extravasation Rates in Cancer Radiology
Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.
Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC
The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.
FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC
MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.
The Greatest Need in NET Research is Funding
Anna Greene, PhD, spoke about how this under-studied disease needs increased funding and more awareness.
Radiologist Shares Procedures for Radioactive Injections, Extravasation
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Funding is the Greatest Need in Neuroendocrine Tumor Research
Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC
Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.
Addressing Unmet Needs in Patients Undergoing Treatment for Rare Lymphomas
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
ctDNA May Help to Predict Early Recurrence in Stage III Melanoma
ctDNA levels may help to predict early recurrence for patients with stage III melanoma before adjuvant therapy and during follow-up.
Cancer Mortality Shows Long-Term Declines Despite COVID-19 Pandemic
An annual report on the status of cancer showed that, from 2018 to 2022, the cancer death rate fell for every race and ethnicity.
Fruquintinib Combo Exhibits Manageable Safety Profile in Pretreated mCRC
Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.
Medical Education May Improve Care for Breast Cancer Minority Populations
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
Low Breast Cancer Guideline-Concordant Care Use Indicates Racial Disparities
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma
Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.
T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer
Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.
Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL
A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.
Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC
Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
